DOCSLIB.ORG

Case of Guillain-Barré Syndrome Following COVID-19 Vaccine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Case of Guillain-Barré Syndrome Following COVID-19 Vaccine Case report BMJ Case Rep: first published as 10.1136/bcr-2021-243629 on 29 June 2021. Downloaded from Case of Guillain- Barré syndrome following COVID-19 vaccine Tanveer Hasan , Mustafizur Khan, Farhin Khan, Ghanim Hamza East Kent Hospitals University SUMMARY raging virus has been started since the beginning NHS Foundation Trust, Guillain-Barré syndrome (GBS) is a rare immune- of 2021 with variable side effects reported in clin- Canterbury, UK mediated disorder of the peripheral nerves. Although ical trials.6 7 However, occurrence of GBS after its cause is not fully understood, the syndrome often COVID-19 vaccination has been reported only Correspondence to twice to date.89 Here, we describe another case of Dr Tanveer Hasan; follows infection with a virus or bacteria, although in rare tanveer_ hasan316@ live. com occasions, vaccination may precede GBS. We describe GBS with a history of receiving first dose of the a case of a 62-year -old woman who presented with Oxford/AstraZeneca COVID-19 vaccine. Accepted 3 June 2021 paraesthesia and progressive weakness of both lower limbs over 3 days. Clinical examination and investigation CASE PRESENTATION findings including lumbar puncture and nerve conduction A- 62- year old woman presented to the acute medical studies were consistent with the diagnosis of GBS. She unit with a 3- day history of gradual weakness of had no history of either diarrhoea or respiratory tract bilateral lower limbs preceded by paraesthesia and infections preceding her presentation. However, she had numbness. Initially, the distal muscles were involved her first intramuscular dose of the Oxford/AstraZeneca which then progressed to involve the proximal COVID-19 vaccine 11 days prior to her presentation. muscles of both lower limbs and finally ascending Although no direct link could be ascertained, the purpose to affect both the arms. She denied back pain, any of this report is to highlight the incidence and consider history of spinal trauma and bowel or bladder this issue while evaluating any case of GBS in the light of dysfunction. She also reported of neuropathic pain the current pandemic and vaccination programme. in the posterior aspects of both legs. There was no recent history of respiratory or diarrhoeal illness before her presentation. Furthermore, she never tested positive for COVID-19 since outbreak of the BACKGROUND pandemic. However, she received her first dose of The term Guillain- Barré syndrome (GBS) tends the Oxford/AstraZeneca COVID-19 vaccine intra- to be used interchangeably with acute idiopathic muscularly 11 days prior to her presentation. She http://casereports.bmj.com/ demyelinating polyneuropathy. The disease results did not suffer from pain at the injection site or in a severe and sometimes lasting paralysis; about influenza-like symptoms during this period. Her one-third of patients develop respiratory failure medical history was significant for bronchiectasis, requiring intensive care unit (ICU) admission and asthma, osteoporosis and migraine. She had no 1 ventilation. GBS is fatal in 3%–5% of patients, and known drug allergies. Her physical examination about two- thirds have residual disability. A mild revealed normal vital signs apart from a blood pres- respiratory or gastrointestinal infection precedes sure reading of 170/100 mm Hg indicating sympa- the neuropathic symptoms by 1–3 weeks, some- thetic over activity, with normal chest expansion and times longer in about 60% of the patients. In recent forced vital capacity. There was no postural drop in years, it has come to be appreciated from serologic blood pressure. Neurological examination findings on September 28, 2021 by guest. Protected copyright. studies that the enteric organism Campylobacter were consistent with a flaccid-type paraplegia of jejuni is the most frequent identifiable causative bilateral lower limbs. The power was noted to be 2 organism. Other less common antecedent events 3/5 in the right leg and 2/5 in the left, both in the or associated illness include cytomegalovirus, proximal and distal muscle groups. Muscle tone was influenza, Mycoplasma pneumoniae, the flavivi- reduced with absence of deep tendon reflexes and ruses including Zika and dengue viruses, and the plantar response. There was no sensory involvement alphavirus, chikungunya.3 The administration of although she had some paraesthesia. Examination of outmoded antirabies vaccines and a New Jersey the upper limbs revealed flaccid type of weakness (swine) influenza vaccine given in the late 1976s with reduced power which was 4/5 in the right arm were associated with a slight increase in the inci- and 3/5 in the left, both proximally and distally. Jerks dence of GBS4 and at least one subsequent influenza were diminished and there was no sensory involve- vaccination programme has been associated with a ment. There was absence of cerebellar signs and © BMJ Publishing Group marginal increase.5 However, no definitive causal Limited 2021. No commercial no evidence of cranial nerve abnormality pointing re-use . See rights and associations have been proven despite these indi- away from a diagnosis of Miller Fisher syndrome. permissions. Published by BMJ. vidual reports being widely recited. Gait could not be examined due to weakness. Other Global cases of the COVID-19 respiratory systemic examinations were unremarkable. To cite: Hasan T, Khan M, Khan F, et al. BMJ Case illness caused by the SARS- CoV-2 have surpassed Rep 2021;14:e243629. 131 million, with a death toll currently at a devas- INVESTIGATIONS doi:10.1136/bcr-2021- tating number of >2.4 million. A worldwide Following admission, routine tests including 243629 mass vaccination programme to fight against this full blood counts, C reactive protein, urea and Hasan T, et al. BMJ Case Rep 2021;14:e243629. doi:10.1136/bcr-2021-243629 1 Case report BMJ Case Rep: first published as 10.1136/bcr-2021-243629 on 29 June 2021. Downloaded from electrolytes, calcium, magnesium, phosphate, liver function pain made the possibility of spinal cord compression less likely. tests and clotting profile were within normal limits. An initial In addition, cord compression and transverse myelitis present chest X- ray to look for infective changes was unremarkable. as spastic paraparesis in contrary to the patient in our case. A urine dipstick test was negative for leucocytes or nitrites. A However, MRI of whole spine was warranted to confidently rule 12-lead ECG showed normal sinus rhythm. COVID-19 PCR test these out. Peripheral neuropathy was another important differ- for SARS- CoV-2 RNA came back negative as a part of routine ential in our case as it presents as flaccid paraparesis or quadripa- hospital admission screen. resis. However, the acute nature of the presentation and normal Basic peripheral neuropathy screen including HbA1c, glucose peripheral neuropathy screen could rule this out, as neuropathy level, vitamin B12 level, folate level, copper level, thyroid func- due to metabolic causes usually have a gradual course. Negative tion tests, protein electrophoresis, paraprotein level, syphilis, ANA and ANCA with normal complement levels ruled out the HIV test and hepatitis screen were performed. The results of possibility of other autoimmune disorders or vasculitis (ANCA these tests were unremarkable. Antinuclear antibody (ANA) was positive vasculitis) as a cause of this acute flaccid neuropathy. negative. Antineutrophil cytoplasmic antibody (ANCA) as well There was no history of intake of any potential drugs which as C3 and C4 levels were done as a part of vasculitis screening could cause neuropathy. In addition, there was no history of and results were within normal limits. exposure to heavy metals or toxins. Our patient denied drinking Owing to the high clinical suspicion of an acute flaccid type of excessive alcohol or recent tick and insect bites. The classic CSF polyneuropathy, a lumbar puncture (LP) was planned. However, findings of albumin- cytological dissociation and NCS findings before proceeding to perform an LP, a non-contrast CT scan of demyelinating, sensorimotor polyneuropathy confirmed the of the head was performed as per hospital protocol to rule out diagnosis of GBS.1 occult intracranial pathologies. The findings, as expected, came back unremarkable. TREATMENT LP was performed and cerebrospinal fluid (CSF) analysis The patient on diagnosis was transferred under the care of revealed albumin-cytological dissociation. CSF protein was neurology team and commenced on intravenous immunoglob- 0.9 g/L (reference range: 0.2–0.4) and CSF white blood cell ulin at a dose of 2 g/kg body weight divided over 5 consecutive count was 1×109/L (reference range: 0–5). Analysis of CSF did days. Unfortunately, her condition gradually deteriorated over not detect bacterial and viral pathogens on BioFire PCR panel. couple of days with persistently falling oxygen saturations on Following this, a non- contrast MRI of the whole spine was pulse oximetry and forced vital capacity <1.5 L (<20 mL/kg performed to rule out spinal pathologies explaining the clinical body weight). She also started experiencing difficulty in speech presentation. The findings from MRI was unremarkable apart and swallowing due to bulbar involvement, necessitating naso- from collapse of the T8 vertebral body without bony infiltration. gastric feeding. Neuropathic pain was managed by gabapentin There was no evidence of spinal cord compression, transverse and paracetamol. She was urgently transferred to ICU for moni- myelitis, spinal cord infarction or spinal stenosis. toring on day 4 of her treatment. During her stay there, she Nerve conduction study (NCS) was performed thereafter developed sepsis secondary to aspiration pneumonia for which which showed marked, demyelinating, sensorimotor poly- she was started on intravenous antibiotics. Considering rapidly http://casereports.bmj.com/ neuropathy (figure 1). There was some sural sparing with no worsening ascending paralysis and to protect the airways, she evidence of acute denervation on electromyography at that time. was intubated, followed by a tracheostomy and put under Ultrasound imaging showed normal nerve cross sectional area mechanical ventilation.
Load more

Recommended publications
  • Assessment Report COVID-19 Vaccine Astrazeneca EMA/94907/2021
    29 January 2021 EMA/94907/2021 Committee for Medicinal Products for Human Use (CHMP) Assessment report COVID-19 Vaccine AstraZeneca Common name: COVID-19 Vaccine (ChAdOx1-S [recombinant]) Procedure No. EMEA/H/C/005675/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 7 1.1. Submission of the dossier ..................................................................................... 7 1.2. Steps taken for the assessment of the product ........................................................ 9 2. Scientific discussion .............................................................................. 12 2.1. Problem statement ............................................................................................. 12 2.1.1. Disease or condition ........................................................................................ 12 2.1.2. Epidemiology and risk factors ........................................................................... 12 2.1.3. Aetiology and pathogenesis .............................................................................
    [Show full text]
  • Ventilation Recommendations Table
    SURVIVING SEPSIS CAMPAIGN INTERNATIONAL GUIDELINES FOR THE MANAGEMENT OF SEPTIC SHOCK AND SEPSIS-ASSOCIATED ORGAN DYSFUNCTION IN CHILDREN VENTILATION RECOMMENDATIONS TABLE RECOMMENDATION #34 STRENGTH & QUALITY OF EVIDENCE We were unable to issue a recommendation about whether to Insufficient intubate children with fluid-refractory, catecholamine-resistant septic shock. However, in our practice, we commonly intubate children with fluid-refractory, catecholamine-resistant septic shock without respiratory failure. RECOMMENDATION #35 STRENGTH & QUALITY OF EVIDENCE We suggest not to use etomidate when intubating children • Weak with septic shock or other sepsis-associated organ dysfunction. • Low-Quality of Evidence RECOMMENDATION #36 STRENGTH & QUALITY OF EVIDENCE We suggest a trial of noninvasive mechanical ventilation (over • Weak invasive mechanical ventilation) in children with sepsis-induced • Very Low-Quality of pediatric ARDS (PARDS) without a clear indication for intubation Evidence and who are responding to initial resuscitation. © 2020 Society of Critical Care Medicine and European Society of Intensive Care Medicine Care Medicine. RECOMMENDATION #37 STRENGTH & QUALITY OF EVIDENCE We suggest using high positive end-expiratory pressure (PEEP) • Weak in children with sepsis-induced PARDS. Remarks: The exact level • Very Low-Quality of of high PEEP has not been tested or determined in PARDS Evidence patients. Some RCTs and observational studies in PARDS have used and advocated for use of the ARDS-network PEEP to Fio2 grid though adverse hemodynamic effects of high PEEP may be more prominent in children with septic shock. RECOMMENDATION #38 STRENGTH & QUALITY OF EVIDENCE We cannot suggest for or against the use of recruitment Insufficient maneuvers in children with sepsis-induced PARDS and refractory hypoxemia.
    [Show full text]
  • Mechanical Ventilation Bronchodilators
    A Neurosurgeon’s Guide to Pulmonary Critical Care for COVID-19 Alan Hoffer, M.D. Chair, Critical Care Committee AANS/CNS Joint Section on Neurotrauma and Critical Care Co-Director, Neurocritical Care Center Associate Professor of Neurosurgery and Neurology Rana Hejal, M.D. Medical Director, Medical Intensive Care Unit Associate Professor of Medicine University Hospitals of Cleveland Case Western Reserve University To learn more, visit our website at: www.neurotraumasection.org Introduction As the number of people infected with the novel coronavirus rapidly increases, some neurosurgeons are being asked to participate in the care of critically ill patients, even those without neurological involvement. This presentation is meant to be a basic guide to help neurosurgeons achieve this mission. Disclaimer • The protocols discussed in this presentation are from the Mission: Possible program at University Hospitals of Cleveland, based on guidelines and recommendations from several medical societies and the Centers for Disease Control (CDC). • Please check with your own hospital or institution to see if there is any variation from these protocols before implementing them in your own practice. Disclaimer The content provided on the AANS, CNS website, including any affiliated AANS/CNS section website (collectively, the “AANS/CNS Sites”), regarding or in any way related to COVID-19 is offered as an educational service. Any educational content published on the AANS/CNS Sites regarding COVID-19 does not constitute or imply its approval, endorsement, sponsorship or recommendation by the AANS/CNS. The content should not be considered inclusive of all proper treatments, methods of care, or as statements of the standard of care and is not continually updated and may not reflect the most current evidence.
    [Show full text]
  • Tracheotomy in Ventilated Patients with COVID19
    Tracheotomy in ventilated patients with COVID-19 Guidelines from the COVID-19 Tracheotomy Task Force, a Working Group of the Airway Safety Committee of the University of Pennsylvania Health System Tiffany N. Chao, MD1; Benjamin M. Braslow, MD2; Niels D. Martin, MD2; Ara A. Chalian, MD1; Joshua H. Atkins, MD PhD3; Andrew R. Haas, MD PhD4; Christopher H. Rassekh, MD1 1. Department of Otorhinolaryngology – Head and Neck Surgery, University of Pennsylvania, Philadelphia 2. Department of Surgery, University of Pennsylvania, Philadelphia 3. Department of Anesthesiology, University of Pennsylvania, Philadelphia 4. Division of Pulmonary, Allergy, and Critical Care, University of Pennsylvania, Philadelphia Background The novel coronavirus (COVID-19) global pandemic is characterized by rapid respiratory decompensation and subsequent need for endotracheal intubation and mechanical ventilation in severe cases1,2. Approximately 3-17% of hospitalized patients require invasive mechanical ventilation3-6. Current recommendations advocate for early intubation, with many also advocating the avoidance of non-invasive positive pressure ventilation such as high-flow nasal cannula, BiPAP, and bag-masking as they increase the risk of transmission through generation of aerosols7-9. Purpose Here we seek to determine whether there is a subset of ventilated COVID-19 patients for which tracheotomy may be indicated, while considering patient prognosis and the risks of transmission. Recommendations may not be appropriate for every institution and may change as the current situation evolves. The goal of these guidelines is to highlight specific considerations for patients with COVID-19 on an individual and population level. Any airway procedure increases the risk of exposure and transmission from patient to provider.
    [Show full text]
  • Mechanical Ventilation Page 1 of 5
    UTMB RESPIRATORY CARE SERVICES Policy 7.3.53 PROCEDURE - Mechanical Ventilation Page 1 of 5 Mechanical Ventilation Effective: 10/26/95 Formulated: 11/78 Revised: 04/11/18 Mechanical Ventilation Purpose Mechanical Artificial Ventilation refers to any methods to deliver volumes of gas into a patient's lungs over an extended period of time to remove metabolically produced carbon dioxide. It is used to provide the pulmonary system with the mechanical power to maintain physiologic ventilation, to manipulate the ventilatory pattern and airway pressures for purposes of improving the efficiency of ventilation and/or oxygenation, and to decrease myocardial work by decreasing the work of breathing. Scope Outlines the procedure of instituting mechanical ventilation and monitoring. Accountability • Mechanical Ventilation may be instituted by a qualified licensed Respirator Care Practitioner (RCP). • To be qualified the practitioner must complete a competency based check off on the ventilator to be used. • The RCP will have an understanding of the age specific requirements of the patient. Physician's Initial orders for therapy must include a mode (i.e. mandatory Order Ventilation/Assist/Control, pressure control etc., a Rate, a Tidal Volume, and an Oxygen concentration and should include a desired level of Positive End Expiratory Pressure, and Pressure Support if applicable. Pressure modes will include inspiratory time and level of pressure control. In the absence of a complete follow up order reflecting new ventilator changes, the original ventilator settings will be maintained in compliance with last order until physician is contacted and the order is clarified. Indications Mechanical Ventilation is generally indicated in cases of acute alveolar hypoventilation due to any cause, acute respiratory failure due to any cause, and as a prophylactic post-op in certain patients.
    [Show full text]
  • Mechanical Ventilation
    Fundamentals of MMeecchhaanniiccaall VVeennttiillaattiioonn A short course on the theory and application of mechanical ventilators Robert L. Chatburn, BS, RRT-NPS, FAARC Director Respiratory Care Department University Hospitals of Cleveland Associate Professor Department of Pediatrics Case Western Reserve University Cleveland, Ohio Mandu Press Ltd. Cleveland Heights, Ohio Published by: Mandu Press Ltd. PO Box 18284 Cleveland Heights, OH 44118-0284 All rights reserved. This book, or any parts thereof, may not be used or reproduced by any means, electronic or mechanical, including photocopying, recording or by any information storage and retrieval system, without written permission from the publisher, except for the inclusion of brief quotations in a review. First Edition Copyright 2003 by Robert L. Chatburn Library of Congress Control Number: 2003103281 ISBN, printed edition: 0-9729438-2-X ISBN, PDF edition: 0-9729438-3-8 First printing: 2003 Care has been taken to confirm the accuracy of the information presented and to describe generally accepted practices. However, the author and publisher are not responsible for errors or omissions or for any consequences from application of the information in this book and make no warranty, express or implied, with respect to the contents of the publication. Table of Contents 1. INTRODUCTION TO VENTILATION..............................1 Self Assessment Questions.......................................................... 4 Definitions................................................................................
    [Show full text]
  • Boston University COVID-19 Response Mechanical Ventilation (HVAC) Systems July 28, 2020
    Boston University COVID-19 Response Mechanical Ventilation (HVAC) Systems July 28, 2020 There is limited scientific data concerning the spread of SARS-CoV-2 (COVID-19) through building heating, ventilating and air conditioning (HVAC) systems. The Centers for Disease Control (CDC) describes SARS-CoV-2 infection as occurring primarily from exposure to respiratory droplets from an infected person. Larger droplets from coughing and sneezing are believed to contain more virus than smaller aerosol particles that may be generated by talking, and large droplets settle rapidly before they might enter HVAC systems. The CDC recommends increasing HVAC system ventilation and filtration to reduce the airborne concentration of SARS-CoV-2 if present in smaller droplets in the air as part of a comprehensive program to control the spread of COVID-19 including frequent hands washing, good respiratory etiquette, appropriate social distancing, face coverings, cleaning and disinfecting surfaces, and staying home if sick. CDC guidance for HVAC system operations and maintenance is based on American Society of Heating, Refrigerating and Air-Conditioning Engineers (ASHRAE) recommendations. BU Heating Ventilating and Air Conditioning (HVAC) COVID-19 Precautions Based on CDC and ASHRAE guidance, Boston University Facilities Management and Operations (FMO) has implemented enhanced maintenance protocols for mechanical and plumbing systems in campus buildings. There are 318 buildings on the Charles River, Fenway and Medical Campuses of which 120 have mechanical ventilation systems and 198 are naturally ventilated using operable windows. Each of the 120 buildings with mechanical ventilation systems is unique in terms of HVAC system design and operation. HVAC systems are designed to meet the state building code and follow American Society of Heating, Refrigeration and Air-Conditioning Engineers (ASHRAE) standards.
    [Show full text]
  • Physical Therapy Practice and Mechanical Ventilation: It's
    Physical Therapy Practice and Mechanical Ventilation: It’s AdVENTageous! Lauren Harper Palmisano, PT, DPT, CCS Rebecca Medina, PT, DPT, CCS Bob Gentile, RRT/NPS OBJECTIVES After this lecture you will be able to describe: 1. Indications for Mechanical Ventilation 2. Basic ventilator anatomy and purpose 3. Ventilator Modes, variables, and equations 4. Safe patient handling a. Alarms and what to expect b. Considerations for mobilization 5. Ventilator Liberation 6. LAB: Suctioning with Bob! INDICATIONS FOR MECHANICAL VENTILATION Cannot Ventilate Cannot Respirate Ventilation: the circulation of air Respiration: the movement of O2 from the outside environment to the cellular level, and the diffusion of Airway protection CO2 in the opposite direction ● Sedation ● Inflammation Respiratory Failure/Insufficiency ● Altered mental status ●Hypercarbic vs Hypoxic ●Vent will maintain homeostasis of CO2 and O2 ●Provides pressure support in the case of fatigued muscles of ventilation VENTILATOR ANATOMY ● Power supply/no battery ● O2 supply and Air supply ● Inspiratory/Expiratory Tubes ● Flow Sensor ● Ventilator Home Screen ● ET tube securing device- hollister ● Connection points - ET tube and trach HOME SCREEN What to observe: ● Mode ● Set rate ● RR ● FiO2 ● PEEP ● Volumes ● Peak and plateau pressures HOME SCREEN ● Mode ● Set rate ● RR ● FiO2 ● PEEP ● Volumes ● Peak and plateau pressures VENTILATION VARIABLES, EQUATIONS, & MODES Break it down ... VARIABLES IN DELIVERY Volume Flow (speed of volume delivery) in L/min Closed loop system ● No flow adjustment
    [Show full text]
  • Policy Brief 002 Update 04.2021.Pdf
    .................................................................................................................................................................. 3 1 Background: policy question and methods ................................................................................................. 7 1.1 Policy Question ............................................................................................................................................. 7 1.2 Methodology ................................................................................................................................................. 7 1.3 Selection of Products for “Vignettes” ........................................................................................................ 10 2 Results: Vaccines ......................................................................................................................................... 13 2.1 Moderna Therapeutics—US National Institute of Allergy ..................................................................... 22 2.2 University of Oxford/ Astra Zeneca .......................................................................................................... 23 2.3 BioNTech/Fosun Pharma/Pfizer .............................................................................................................. 25 2.4 Janssen Pharmaceutical/ Johnson & Johnson .......................................................................................... 27 2.5 Novavax ......................................................................................................................................................
    [Show full text]
  • Mechanical Ventilation in Patients with Sepsis
    mechanical ventilation in patients with sepsis Armin Kalenka, MD, Ph.D. head of anaesthesia/intensive care med [email protected] 2 conflict of interest consultant, travel expenses, lecture fees 3 What is your focus for a patient on the ventilator? • Oxygenation • CO2 Elimination • Lung protection 4 Best practice in mechanical ventilation? • VT: 6 ml/kg pbw for all patients? • NEJM 2000 • PEEP: ARDS network table based on Oxygenation? • NEJM 2000 or NEJM 2004 • High PEEP: for severe ARDS • JAMA 2010 • Prone: for severe ARDS • NEJM 2013 • NMB: for severe ARDS • NEJM 2010 • No NIV for severe ARDS • AJRCCM 2017 5 6 ARDS and Sepsis ARDS Sepsis 7 ARDS and Sepsis Sepsis ARDS 8 ARDS and Sepsis ARDS Sepsis 9 How often is ARDS in severe sepsis? Shock; 2013:40: 375-382 10 Fluids, Sepsis and ARDS LIPS: adult patients with one or more ARDS risk factors admitted to the hospital through the Emergency Department or admitted for high-risk elective surgery. Ann Intensive Care 2017; 7: 11 11 Best practice in mechanical ventilation? • VT: 6 ml/kg pbw for all patients? • NEJM 2000 • PEEP: ARDS network table based on Oxygenation? • NEJM 2000 or NEJM 2004 • High PEEP: for severe ARDS • JAMA 2010 • Prone: for severe ARDS • NEJM 2013 • NMB: for severe ARDS • NEJM 2010 • No NIV for severe ARDS • AJRCCM 2017 ? 12 Normalisation because of unknown size of the „baby“ lung the driving pressure: ΔP = VT/Comp 13 tidal volume should not longer be the target! 14 goal partial pressure of oxygen in arterial blood range of 55–80 mm Hg fiO2 of 0.5 = 0 increasing deaths with higher oxygenation in all groups of ARDS severity Crit Care Med 2017; DOI: 10.1097/CCM.0000000000002886 15 n = 861 Oxygenation should not be the 6 ml∙kg-1: n = 432 key parameter 12 ml∙kg-1: n = 429 for the ventilator settings ! Mortality [%] paO2/fiO2 190 50 * * * 40 180 30 170 20 160 10 150 0 0 6 ml∙kg-1 12 ml∙kg-1 1 2 7 days 16 alveolar stability is unrelated to arterial oxygenation Andrews et al.
    [Show full text]
  • Acute Respiratory Distress Syndrome and Time to Weaning Off the Invasive Mechanical Ventilator Among Patients with COVID-19 Pneumonia
    Journal of Clinical Medicine Article Acute Respiratory Distress Syndrome and Time to Weaning Off the Invasive Mechanical Ventilator among Patients with COVID-19 Pneumonia Jose Bordon 1,2,3,*, Ozan Akca 3,4,5,6, Stephen Furmanek 3,4,6, Rodrigo Silva Cavallazzi 3,7, Sally Suliman 7, Amr Aboelnasr 3,4,6, Bettina Sinanova 1 and Julio A. Ramirez 3,4,6 1 Washington Health Institute, Washington, DC 20017, USA; [email protected] 2 Department of Medicine, George Washington University Medical Center, Washington, DC 20037, USA 3 Center of Excellence for Research in Infectious Diseases (CERID), University of Louisville, Louisville, KY 40292, USA; [email protected] (O.A.); [email protected] (S.F.); [email protected] (R.S.C.); [email protected] (A.A.); [email protected] (J.A.R.) 4 Department of Anesthesiology and Perioperative Medicine, University of Louisville, Louisville, KY 40292, USA 5 Comprehensive Stroke Clinical Research Program (CSCRP), University of Louisville, Louisville, KY 40292, USA 6 Division of Infectious Diseases, University of Louisville, Louisville, KY 40292, USA 7 Division of Critical Care Medicine, University of Louisville, Louisville, KY 40292, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-240-426-8890 Citation: Bordon, J.; Akca, O.; Abstract: Acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19) Furmanek, S.; Cavallazzi, R.S.; pneumonia is the main cause of the pandemic’s death toll. The assessment of ARDS and time Suliman, S.; Aboelnasr, A.; Sinanova, on invasive mechanical ventilation (IMV) could enhance the characterization of outcomes and B.; Ramirez, J.A.
    [Show full text]
  • Noninvasive Ventilation for Treatment of Acute Respiratory Failure in Patients Undergoing Solid Organ Transplantation a Randomized Trial
    CARING FOR THE CRITICALLY ILL PATIENT Noninvasive Ventilation for Treatment of Acute Respiratory Failure in Patients Undergoing Solid Organ Transplantation A Randomized Trial Massimo Antonelli, MD Context Noninvasive ventilation (NIV) has been associated with lower rates of en- Giorgio Conti, MD dotracheal intubation in populations of patients with acute respiratory failure. Maurizio Bufi, MD Objective To compare NIV with standard treatment using supplemental oxygen ad- ministration to avoid endotracheal intubation in recipients of solid organ transplanta- Maria Gabriella Costa, MD tion with acute hypoxemic respiratory failure. Angela Lappa, MD Design and Setting Prospective randomized study conducted at a 14-bed, gen- Monica Rocco, MD eral intensive care unit of a university hospital. Alessandro Gasparetto, MD Patients Of 238 patients who underwent solid organ transplantation from Decem- ber 1995 to October 1997, 51 were treated for acute respiratory failure. Of these, 40 Gianfranco Umberto Meduri, MD were eligible and 20 were randomized to each group. Intervention Noninvasive ventilation vs standard treatment with supplemental oxy- N THE PAST 2 DECADES, ADVANCE- gen administration. ments in immunosuppressive strat- egies and major breakthroughs in Main Outcome Measures The need for endotracheal intubation and mechanical surgical and organ preservation ventilation at any time during the study, complications not present on admission, du- ration of ventilatory assistance, length of hospital stay, and intensive care unit mor- Itechniques have transformed organ tality. transplantation into a therapy for an in- creasing population of patients with end- Results The 2 groups were similar at study entry. Within the first hour of treatment, 14 patients (70%) in the NIV group, and 5 patients (25%) in the standard treatment stage organ failure.
    [Show full text]